Income statement
CAD
Annual
| Metric | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 52K | 0 |
| Gross Profit | 0 | 0 | 0 | 16K | 0 |
| Operating Income | -41M | -978K | -397K | -290K | -546K |
| EBITDA | -41M | -41M | -395K | -395K | -289K |
| Net Income | -60M | -989K | -778K | -299K | -551K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.00004
+0.00% today
1Y Change
-96.00%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Transnational Cannabis Ltd. (TRCNF) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 96.0% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -522.9%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -522.9%, free cash flow -1669.6% with operating margin 0.0% and ROIC -60.5%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TRCNF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TRCNF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TRCNF Max Drawdown
-96.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TRCNF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
-100.0% YoY
FY Net Income
-$551.2K
-84.4% YoY
Free Cash Flow
-$546.5K
-2257.8% YoY
Revenue Growth
+0.0%
EPS Growth
-522.9%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
CAD
| Metric | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 52K | 0 |
| Gross Profit | 0 | 0 | 0 | 16K | 0 |
| Operating Income | -41M | -978K | -397K | -290K | -546K |
| EBITDA | -41M | -41M | -395K | -395K | -289K |
| Net Income | -60M | -989K | -778K | -299K | -551K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1M | 73K | 14K | 10K | 11K |
| Total Assets | 70M | 106K | 25K | 143K | 255K |
| Total Liabilities | 7M | 202K | 294K | 148K | 63K |
| Shareholder Equity | 63M | -96K | -269K | -5K | 192K |
| Total Debt | 5M | 15K | 17K | 12K | 0 |
| Net Debt | 4M | -58K | 3K | 2K | -11K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
546K
-2257.8% YoY
Capital Expenditures
0
Free Cash Flow
546K
-2257.8% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-192.2%
Debt / Equity
0.09x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.